The FDA is the leading science-based consumer protection agency in the world. Three former senior officials write about what they hope the Trump administration doesn’t change.

Dr. Robert M. Califf bid farewell to his role as Commissioner of the U.S. Food and Drug Administration in a reflective post on X, formerly

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) active Investigational New Drug (IND) applications. These INDs include the EBVALLO (tabelecleucel) program for patients two years of age and older with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD),

After decades of debate, the Food and Drug Administration (FDA) has announced a ban on Red Dye No. 3, a synthetic food coloring that’s been linked to cancer in male lab rats. The decision comes after a petition filed in 2022 by advocacy groups,

Red dye No. 3 has been permissible for use in food despite the Delaney Clause of the FDA’s Federal Food, Drug, and Cosmetic Act. The clause, in part, “prohibits the FDA from approving a color additive that is ingested if it causes cancer in animals or humans when ingested,” according to the agency .

The Trump administration’s food regulatory agenda will come into sharper focus once nominees for the U.S. Department of Health and Human

More than a dozen cats have been killed or sickened by bird flu that is spreading in raw food products, the Food and Drug Administration says, prompting a federal probe into how the virus got into the pet food supply chain.

Amid a deluge of executive actions, the Trump administration has asked federal health agencies to pause external communications, such as regular scientific reports, updates to websites and health advisories,

Koh Young Technology, a South Korean mid-sized company specializing in 3D inspection equipment, has seen its stock price surge by about 64% since Jan. 2025. The jump follows news on Jan. 20 that the company’s medical robot is set to enter the U.

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine) as the first monotherapy for adults with treatment-resistant depression,

The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its own. It was approved in 2019 to treat severe depression.